Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters
 

Hepatitis C; Chronic Clinical Trials

A listing of Hepatitis C; Chronic medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (11) clinical trials

Continuing Treatment With Pegasys and Copegus

Prospective, multicentre, randomized, open-label comparative study According to our national guideline of management of patient with chronic viral hepatitis, patients need to stop therapy if they do not achieve response. These patients can enter to the study at two time points: - at week 16, if HCV RNS PCR measured ...

Phase

RIBAJUSTE Clinical Trial Investigating the Efficacy and Safety of Dose Adaptation of Ribavirin

The aim of this study is to compare two therapeutical strategies concerning the combination therapy (peginterferon alfa-2a and ribavirin) in naïve patients with chronic hepatitis C of genotype 1. "Reference" strategy corresponding to standards of care recommended by the French consensus conference versus "Test" strategy corresponding to adaptation strategy of ...

Phase

Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC

The study will recruit 150 patients with HCV related HCC All the studied patients underwent or will undergo one of the curative interventions for HCC either hepatic resection or thermal ablation . after 1 month of achievement of laboratory and radiological response to HCC intervention the patient will be treated ...

Phase

Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C/Hepatitis B Co-Infection and Chronic Hepatitis C

Around the world, the majority of hepatitis C patients suffer a monoinfected chronic HCV infection. Current regimen on this group of patients received much attention and resulted in rapid advances [McHutchison et al, 1998]. However, there are certain understudied populations with chronic hepatitis C [Strader DB, 2002]. One important group ...

Phase

Methacetin Breath Test in HCV Patients With Normal and Near-Normal ALT

The rational for using MBIT in the management of HCV in patients with persistently normal (and slightly elevated) ALT: - If MBIT is impaired, this indicates fibrosis >2: a trigger to begin treatment - This strategy will enable treating patients with relatively severe disease that was not detected by biopsy. ...

Phase

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Treatment-Na ve and Treatment-Experienced Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection

A Phase 3, double-blind (DB), placebo-controlled study to evaluate the efficacy and safety of ABT-493/ABT-530 in non-cirrhotic chronic hepatitis C virus (HCV) genotype (GT)1 to GT6-infected Asian participants with or without human immunodeficiency virus (HIV) co-infection who are HCV treatment-nave or treatment-experienced with interferon (IFN) (alpha, beta or pegylated interferon ...

Phase

A Study to Evaluate the Pharmacokinetics Safety and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection

An open-label study to assess the pharmacokinetics (PK), safety, and efficacy of glecaprevir (GLE)/pibrentasvir (PIB) in pediatric participants divided into 4 age groups: 3 to < 6, 6 to < 9, 9 to < 12, and 12 to < 18 years of age. Within each age group, some participants will ...

Phase

A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Na ve Adults With Chronic Hepatitis C Virus (HCV) Genotype 1 2 4 5 or 6 Infection and Compensated Cirrhosis

A Phase 3b, single arm, open-label, multicenter study to evaluate the safety and to demonstrate the non-inferiority of the sustained virologic response 12 weeks post dosing (SVR12) rates of 8 weeks of treatment with the glecaprevir (GLE)/pibrentasvir (PIB) combination regimen to the historical SVR12 rate of 12 weeks of treatment ...

Phase

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Treatment-Na ve and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection

This is a Phase 3, single-arm, open-label, multicenter study to evaluate the efficacy and safety of ABT-493/ABT-530 in chronic hepatitis C virus (HCV) genotype (GT)1 to GT6-infected Asian participants with compensated cirrhosis with or without Human Immunodeficiency Virus (HIV) co-infection who are HCV treatment-nave or treatment-experienced with interferon (IFN) (alpha, ...

Phase

8 Weeks Versus 12 Weeks of Elbasvir/Grazoprevir in Treatment-na ve CHC With Mild Fibrosis

Grazoprevir, an HCV nonstructural protein 3/4A (NS3/4A) inhibitor 100 mg, plus elbasvir, an HCV NS5A inhibitor 50 mg fixed dose combination, Zepatier, achieved high SVR12 rates of > 95 % in treatment-nave, experienced cirrhotic and non-cirrhotic patients with genotype 1, 4, or 6 infection. Zepatier, 12 to 16 weeks, was ...

Phase